Adenosine Monophosphate–Activated Protein Kinase: A Central Regulator of Metabolism with Roles in Diabetes, Cancer, and Viral Infection

D.G. HARDIE
Division of Cell Signalling and Immunology, College of Life Sciences, University of Dundee, Dundee DD1 5EH, United Kingdom
Correspondence: d.g.hardie@dundee.ac.uk

Adenosine monophosphate–activated protein kinase (AMPK) is a cellular energy sensor activated by metabolic stresses that inhibit catabolic ATP production or accelerate ATP consumption. Once activated, AMPK switches on catabolic pathways, generating ATP, while inhibiting cell growth and proliferation, thus promoting energy homeostasis. AMPK is activated by the antidiabetic drug metformin, and by many natural products including “nutraceuticals” and compounds used in traditional medicines. Most of these xenobiotics activate AMPK by inhibiting mitochondrial ATP production. AMPK activation by metabolic stress requires the upstream kinase, LKB1, whose tumor suppressor effects may be largely mediated by AMPK. However, many tumor cells appear to have developed mechanisms to reduce AMPK activation and thus escape its growth-restraining effects. A similar phenomenon occurs during viral infection. If we can establish how down-regulation occurs in tumors and virus-infected cells, there may be therapeutical avenues to reverse these effects.

Adenosine monophosphate (AMP)–activated protein kinase (AMPK) is a protein kinase originally discovered via its ability to inactivate two key enzymes of lipid biosynthesis, that is, acetyl-CoA carboxylase (Carlson and Kim 1973) and 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase (Beg et al. 1973). Both activities were shown to be allosterically activated by AMP (Yeh et al. 1980; Ferrer et al. 1985), but it was not realized that they were catalyzed by the same protein kinase until the author’s laboratory provided evidence for this (Carling et al. 1987). Since it soon became clear that this protein kinase had multiple downstream targets, it was renamed the AMP-activated protein kinase (AMPK) (Munday et al. 1988; Hardie et al. 1989).

AMPK exists as heterotrimeric complexes comprising a catalytic α subunit and regulatory β and γ subunits. In mammals, each subunit occurs as multiple isoforms encoded by multiple genes (α1/α2; β1/β2, γ1/γ2/γ3), which assemble to form up to 12 heterotrimeric combinations (Hardie 2007), with splice variants further increasing the diversity. From the early studies of HMG-CoA reductase kinase, it was realized that the kinase was activated by phosphorylation by upstream kinases (Ingebritsen et al. 1978). The manner in which this interfaces with effects of adenine nucleotides, allowing the kinase to act as an energy sensor, is discussed below.

ROLE OF AMPK ORTHOLOGS IN NONMAMMALIAN EUKARYOTES

Orthologs of AMPK genes/subunits occur in essentially all eukaryotes; those in budding yeast (Saccharomyces cerevisiae) had been studied for several years before it was realized that they were related to AMPK. The S. cerevisiae kinase is also a heterotrimeric complex (referred to here as the SNF1 complex) with the α subunit encoded by SNF1, the β subunit by three alternate genes (SIP1, SIP2, GAL83) and the γ subunit by SNF4 (Hardie et al. 1998). All are required for growth of budding yeast on carbon sources other than glucose, although any one of the three β subunit genes is sufficient (Schmidt and McCartney 2000). Nonglucose carbon sources whose utilization requires a functional SNF1 complex include fermentable sugars such as sucrose, maltose, and galactose, and nonfermentable sources such as glycerol and ethanol. In yeast grown solely on glucose, the Snf1 complex is required for the diauxic shift that occurs as glucose runs low. During this shift, growth slows and there is a switch from fermentative to oxidative metabolism to generate ATP (Hedbacker and Carlson 2008). Diploid strains also undergo meiosis and sporulation in response to glucose starvation, and this also requires a functional SNF1 complex (Honigberg and Lee 1998).

AMPK orthologs are also found in plants (Alderson et al. 1991; Mackintosh et al. 1992). Deletion of the two catalytic subunit genes in a primitive plant, the moss Physcomitrella patens, produced no phenotype when the plants were grown in continuous light, but the plants failed to grow on more physiological alternate light/dark cycles (Thelander et al. 2004). Since darkness is the equivalent of starvation for a photosynthetic organism, and the yeast ortholog is required during glucose starvation, this suggested that the ancestral role of AMPK was in response to starvation for the key carbon source. Consistent with this, overexpression of the catalytic subunit in...
Arabidopsis thaliana caused resistance to carbohydrate starvation in low light levels, whereas down-regulation of the catalytic subunits resulted in a stunted growth, associated with a failure to execute the transcriptional switch and mobilization of stored starch that normally occurs during a dark period. However, in this organism the growth phenotype was not rescued by continuous illumination (Baena-Gonzalez et al. 2007).

In the nematode worm Caenorhabditis elegans, starvation and other stresses in early life result in an extension of life span, but this did not occur when one of the two AMPK catalytic subunits (AAK-2) was knocked out (Apfeld et al. 2004). AAK-2 is required for life-span extension in response to treatment with the plant product resveratrol, and to some but not all protocols of dietary restriction (Greer et al. 2007; Greer and Brunet 2009). It is also required for the arrest of germ cell development that occurs on dietary restriction (Narbone and Roy 2006), and for inhibition of triglyceride breakdown when worms enter the long-lived Dauer larval form (Narbone and Roy 2009). Thus, C. elegans AMPK is involved in coupling the availability of nutrients to development and sexual maturation.

MAMMALIAN AMPK—STRUCTURE AND REGULATION

The functional domains within the α, β, and γ subunits of AMPK are illustrated in Figure 1. The α subunit contains the kinase domain, with the conserved threonine residue that is the target for upstream kinases (Thr172 in human α1) located within the activation loop. Phosphorylation at Thr172 is required for kinase activity and function in all species from yeast to man, and with the human kinase causes >100-fold activation (Estruch et al. 1992; Hawley et al. 1996; Stein et al. 2000). The upstream kinases that phosphorylate this site were initially identified in S. cerevisiae (Hong et al. 2003; Sutherland et al. 2003), leading to the subsequent identification of LKB1 as the major upstream kinase in mammalian cells (Hawley et al. 2003; Woods et al. 2003). LKB1 had been previously identified (Hemminki et al. 1998) as a tumor suppressor mutated in Peutz–Jeghers syndrome, an inherited susceptibility to cancer in humans. The LKB1 gene is also mutated in many spontaneous, noninherited cancers (Sanchez-Cespedes et al. 2002; Wingo et al. 2009). The discovery that LKB1 was upstream of AMPK introduced for the first time a link between AMPK and cancer. It remains uncertain whether the tumor suppressor effects of LKB1 are entirely mediated by AMPK because, in addition to the two catalytic subunit isoforms of AMPK, LKB1 also activates 12 AMPK-related kinases (whose functions are less well understood than those of AMPK) via phosphorylation of the residues equivalent to Thr172 (Lizcano et al. 2004). LKB1 is only active when present as a heterotrimeric complex with two accessory subunits, STRAD and MO25 (Hawley et al. 2003), but there is currently little evidence that it is regulated. It appears to phosphorylate AMPK constitutively, and the effects of adenine nucleotides on phosphorylation of Thr172 are mediated by binding to AMPK, and not to LKB1 (see below).

Almost as soon as LKB1 was identified as a kinase phosphorylating Thr172, it was realized that there must be others, as some Thr172 phosphorylation was evident even in cells lacking LKB1. The best characterized of these are the Ca<sup>2</sup>+-activated, calmodulin-dependent kinase kinases (especially CaMKKβ), which also act as upstream kinases for the calmodulin-dependent kinases, CaMKI and CaMKIV (Hawley et al. 2005; Hurley et al. 2005; Woods et al. 2005). These cause AMPK activation (in an AMP-independent manner) in response to increases in intracellular Ca<sup>2</sup>+, and this mechanism is responsible for AMPK activation in response to depolarization of neurones (Hawley et al. 2005), thrombin in endothelial cells (Stahmann et al. 2006), and stimulation of the T cell receptor in T cells (Tamas et al. 2006). Unlike LKB1, the CaMKKs do not appear to phosphorylate and activate any of the AMPK-related kinases (Fogarty et al. 2010).

The amino-terminal kinase domain on the α subunit of AMPK is immediately followed (Fig. 1) by the “auto-inhibitory domain,” so called because truncated constructs containing this domain plus the kinase domain are much less active that those containing the kinase domain alone (Goransson et al. 2007; Pang et al. 2007).
The auto-inhibitory domain (AID) shows weak sequence similarity to the ubiquitin-associated (UBA)-like domains found in the same location in several of the AMPK-related kinases. A structure of a carboxy-terminally truncated α subunit of the Schizosaccharomyces pombe AMPK ortholog revealed that the AID forms a bundle of three α helices that interacts with the large and small lobes of the kinase domain on the opposite side to the active site (Chen et al. 2009). It was proposed that the AID is involved in the mechanism by which AMP causes allosteric activation, because mutations predicted to disrupt the interaction between the kinase domain and the AID (in the context of the mammalian heterotrimer) increased the basal activity and abolished AMP activation.

The carboxy-terminal domain of the α subunit forms a compact globular domain required for formation of the heterotrimeric complex (Crute et al. 1998). The carboxy-terminal domain (CTD) of the β subunit wraps around this α-CTD and then terminates with two antiparallel strands. These form α β sheet with a third strand provided by the amino terminus of the γ subunit; this β sheet forms the conserved “core” of the αβγ complex in S. cerevisiae, S. pombe, and mammals (Amodeo et al. 2007; Townley and Shapiro 2007; Xiao et al. 2007). Nearer to the center of the β subunit (Fig. 1) is a conserved domain that is a member of the “CBM20” family of carbohydrate-binding modules (CBMs) (Machovic and Janecek 2006). CBMs are most commonly found (in both prokaryotes and eukaryotes) in enzymes that metabolize starch, glycogen, and related polysaccharides, where their function appears to be to localize the associated catalytic domain on the polysaccharide substrate. The CBM in the AMPK-β subunit causes the complex to associate with glycogen particles in intact cells (Hudson et al. 2003; Polekhina et al. 2003), and AMPK also associates with the surface of glycogen particles in vivo (Bendayan et al. 2009). The function of this association remains uncertain, although AMPK does phosphorylate two proteins that are targeted to glycogen, that is (1) muscle glycogen synthase (mGS), whose phosphorylation at site 2 causes inactivation (Carling and Hardie 1989; Jørgensen et al. 2004), and (2) R5/PTG, which targets the catalytic subunit of protein phosphatase-1 (PP1) to glycogen (Vernia et al. 2009). Phosphorylation of R5 is proposed to promote its ubiquitylation and degradation, so that phosphorylation of mGS and R5 by AMPK would not only cause inactivation of mGS, but also dissociation from glycogen of the protein phosphatase (PP1) that reactivates it, the two effects cooperating to inhibit glycogen synthesis. We have shown that certain preparations of glycogen, and also synthetic oligosaccharides based on glycogen, can inhibit AMPK (McBride et al. 2009). Our current hypothesis is that degradation of glycogen (e.g., during exercise in muscle) leads to changes in structure that cause increasing inhibition of the bound AMPK. By inhibiting phosphorylation of mGS and R5/PTG, this would lead to net dephosphorylation and activation of mGS, thus ensuring that glycogen is rapidly replenished whenever it becomes depleted. This would help to explain the paradox that mGS is found to be dephosphorylated and activated following exercise (Aschenbach et al. 2001), despite the fact that AMPK (which phosphorylates and inactivates mGS) is switched on during exercise (Winder and Hardie 1996). Our model suggests that the pool of AMPK bound to glycogen is regulated by the structural state of glycogen particles, a mechanism not available to other pools of AMPK.

How do AMP and other adenine nucleotides regulate mammalian AMPK? Following the initial observations that AMP allosterically activates AMPK (Yeh et al. 1980; Ferrer et al. 1985), my laboratory showed that AMP also promoted net phosphorylation of Thr172, and hence activation, by a second mechanism (Moore et al. 1991). We subsequently reported that AMP both promoted phosphorylation (Hawley et al. 1995) and inhibited dephosphorylation (Davies et al. 1995), so that (combined with the allosteric effect) AMP activates AMPK by a three-pronged mechanism. When highly purified preparations of bacterially expressed AMPK became available, the effect of AMP on dephosphorylation was confirmed, but the effect on phosphorylation by LKB1 was not (Suter et al. 2006). It was proposed that the apparent effect on phosphorylation of Thr172 may have been an artifact caused by contamination of the kinase preparations used with protein phosphatases (Sanders et al. 2007). However, more recently it has been shown that the lack of effect of AMP on phosphorylation of bacterially expressed AMPK by LKB1 may have been due to the fact that, unlike the native complex, it was not myristoylated at the amino terminus of the β subunit (Oakhill et al. 2010).

Studies using a photoaffinity analog of AMP identified the γ subunit as the likely location of the adenine nucleotide–binding sites (Cheung et al. 2000). Additional clues came from observations that dominant mutations in the gene encoding the human γ2 isofrom (expressed at high levels in cardiac muscle), which were associated with a heart disease characterized by premature excitation of the large chambers (Blair et al. 2001; Gollob et al. 2001), were shown to interfere with binding of, and activation by, AMP (Daniel and Carling 2002; Adams et al. 2004; Scott et al. 2004). The γ subunits in all AMPK orthologs contain four tandem repeats of a sequence known as a CBS repeat, so called because they are also found in the enzyme cystathionine β-synthase (Bateman 1997). CBS repeats occur in around 20 proteins in the human genome, although in most cases there are only two tandem repeats, rather than four. Two repeats form a domain (termed a Bateman domain; Kemp 2004) that binds regulatory ligands containing adenosine, usually AMP, ADP, or ATP but, in one case (cystathionine β-synthase), S-adenosylmethionine (Scott et al. 2004).

The structures of the core AMPK complexes from S. cerevisiae, S. pombe, and mammals show that the two Bateman domains formed by CBS1:CBS2 and CBS3:CBS4 assemble head to head to form a flattened disk with one CBS repeat in each quadrant (Amodeo et al. 2007; Townley and Shapiro 2007; Xiao et al. 2007). This symmetrical arrangement creates four clefts...
near the center where AMP, ADP, or ATP (referred to below as AXP) might bind, two accessible from one side of the disk and two from the other. However, in mammalian AMPK only three are occupied, with the fourth being vacant, possibly because aspartate side chains that interact with ribose hydroxyls of AXPs in the other three sites are not conserved. Although each molecule of bound AXP interacts with side chains from more than one CBS repeat, a useful convention (Kemp et al. 2007) is to number the sites according to the CBS repeat bearing the aspartate residue interacting with the ribose ring. Recent binding studies have helped to define the functions of the three sites (Xiao et al. 2011). Site 1 binds all three AXPs with similar high affinities and, based on the concentrations of AMP that cause allosteric activation, binding at this site appears to be responsible for this effect, which is only observed with AMP (Carling et al. 1989; Xiao et al. 2011). Site 2 is the empty site, whereas site 3 again binds all three AXPs with similar affinities, although their affinities are about 50-fold lower than at site 1. Site 3 appears to be the site at which AMP binding inhibits dephosphorylation of Thr172, and it has recently been shown that binding of ADP (but not ATP) has the same effect (Xiao et al. 2011). ADP binding at site 3 also appears to promote phosphorylation of Thr172 by upstream kinases (Oakhill et al. 2011). Site 4, whose function remains unclear, binds AMP very tightly; AMP is already present in this site when recombinant AMPK is purified from E. coli, and it does not exchange with ADP or ATP (Xiao et al. 2007).

The recent findings (Oakhill et al. 2011; Xiao et al. 2011) that binding of AMP (as well as AMP) at site 3 promotes net phosphorylation of Thr172 seem likely to be important under physiological circumstances. Because of the action of the mitochondrial ATP synthase (and glycolysis), cellular ATP:ADP ratios in unstressed cells are maintained at around 10:1. The most important reaction producing and consuming AMP is catalyzed by adenylate kinase \(2\text{ADP} \leftrightarrow \text{ATP} + \text{AMP}\), a near-equilibrium reaction with an equilibrium constant close to 1. If the ATP:ADP ratio is 10:1 and the adenylate kinase reaction is at equilibrium, the ATP:AMP ratio would be around 100:1. Although the concentration of AMP rises steeply as the ATP:ADP ratio falls during metabolic stress (Hardie and Hawley 2001), it will usually remain much lower than those of ADP and ATP, and it is therefore difficult to see how it could compete effectively with the other AXPs for binding to the \(\gamma\) subunit. However, the concentration of ADP is much closer to that of ATP, so that it could more effectively compete. Moreover, Mg-ATP\(^{2-}\) has a lower affinity for the \(\gamma\) subunit than free ATP (Xiao et al. 2011) and because most cellular ATP is present in the form of the Mg complex, this further explains how ADP can compete with ATP. These arguments suggest that the AMPK system may normally be monitoring fluctuations in ADP:ATP, with increases in this ratio causing activation by promoting net phosphorylation of Thr172. The effect of AMP to allosterically activate the kinase, which multiplies with the effect of Thr172 phosphorylation to produce \(>1000\)-fold activation overall, may only come into play during more severe metabolic stresses, when AMP levels might approach those of ADP and free ATP. This regulatory system, while complex (Fig. 2), would allow AMPK to respond to energy stress across a broad range of cellular ADP:ATP and AMP:ATP ratios, and with a wide dynamic range of \(>1000\)-fold activation.

A plausible mechanism to explain how binding of AMP or ADP at site 3 prevents dephosphorylation of Thr172 has been suggested by a new structure in which an almost full-length \(\alpha1\) subunit (including the kinase domain phosphorylated on Thr172) was crystallized in complex with full-length \(\gamma1\) and the \(\beta1\)-CTD (Xiao et al. 2011). As in the original structure that lacked the kinase domain (Xiao et al. 2007), the CTDs of \(\alpha\) and \(\beta\) associate closely together, but in the new structure they also interact with the activation loop of the kinase domain, hindering access to Thr172 of protein phosphatases that would dephosphorylate the residue. The kinase domain and the \(\alpha\)-CTD, at opposite ends of the \(\alpha\) subunit, are connected by a long extended peptide that wraps around the \(\gamma\) subunit, resembling two “arms” with the hands clasped together, holding the \(\gamma\) subunit in a tight embrace (Fig. 3, right). The “hands” form a structure known as the \(\alpha\) hook, which contacts the exposed phosphate group of AMP bound at site 3. Comparison with a previous partial structure with ATP bound at this site (Xiao et al. 2007) indicates that binding of ATP, but not ADP or AMP, might disrupt the interaction with the \(\alpha\) hook. This suggests a model (Xiao et al. 2011) in which binding of ATP at site 3 prevents the association of the...
and acutely activate AMPK in skeletal muscle, thus (Yamauchi et al. 2002), which are secreted by adipocytes kines leptin (Minokoshi et al. 2002) and adiponectin in mammals also appear to have acquired the ability to otes, cytokines that regulate whole-body energy balance responses to glucose starvation in multicellular eukary-otes and may still be involved in cell-autonomous 2007). Although AMPK evolved in single-celled eukary-isms increase (e.g., exercise hypoxia, hypoglycemia), or that accelerate ATP con-}
hypoglycemia (Claret et al. 2007). Consistent with this, down-regulation of α2 in the ventromedial hypothalamus of rats, using short hairpin RNAs delivered by viral vectors, resulted in a defective counter-regulatory response to hypoglycemia, that is, a failure to secrete glucagon from the pancreas and epinephrine from the adrenal medulla (McCrimmon et al. 2008). Taken together, these findings suggest that a kinase that evolved to mediate the cell-autonomous response to glucose starvation in single-celled eukaryotes has retained this function in multicellular organisms. However, it now senses hypoglycemia in the hypothalamus to initiate complex physiological responses, that is, regulation of feeding behavior and hormone secretion.

In most cases, the mechanisms by which AMPK is activated (and inhibited) by cytokines remain unclear. AMPK is also activated by many drugs and xenobiotics, including drugs used clinically in the treatment of type 2 diabetes, such as metformin (Zhou et al. 2001) and thiazolidinediones (Fryer et al. 2002). Other xenobiotics that activate AMPK include plant products that are "naturaceuticals" (e.g., resveratrol present in grapes and red wine [Baur et al. 2006] and epigallocatechin gallate present in green tea [Hwang et al. 2007]), and plant products used in traditional Chinese medicine (e.g., berberine [Lee et al. 2006] and hispidelin [Lin et al. 2010]). Interestingly, metformin was derived from galegine, a natural product of the plant Galega officinalis, which was used in traditional European herbal medicine; galegine is also a potent activator of AMPK (Mooney et al. 2008).

Although some of these AMPK-activating drugs and xenobiotics can be classed as polyphenols, there are no other structural similarities between them, so an obvious question was how they all activate AMPK. Many are secondary plant metabolites, and an interesting possibility was that they are produced by plants to discourage grazing by herbivores or insects, or protect against pathogen infection. One way of achieving this would be for these defense compounds to inhibit mitochondrial ATP synthesis, making them poisonous to grazing animals or pathogens. However, this mechanism would also activate AMPK, a very sensitive indicator of mitochondrial poisoning. In support of this idea, G. officinalis (also known as goat’s rue) is poisonous to herbivores and classed as a noxious weed in the United States, while resveratrol is produced by grapes in response to fungal infection. In addition, metformin has been reported to inhibit complex I of the mitochondrial respiratory chain (El-Mir et al. 2000; Owen et al. 2000), and resveratrol to inhibit mitochondrial F1 ATP synthase (Gledhill et al. 2007). To test whether activation of AMPK by these compounds was indeed secondary to inhibition of mitochondrial function, we made use of isogenic HEK-293 cell lines expressing either the wild-type γ2 subunit (in which AMPK complexes are sensitive to increases in cellular AMP/ADP), or γ2 with a mutation in site 3 (R531G, which renders AMPK complexes insensitive to such increases; Hawley et al. 2010). This allowed us to show that many of these drugs and xenobiotics (e.g., metformin, galegine, thiazolidinediones, phenobarbital, berberine) activate AMPK by inhibiting the respiratory chain, while others (e.g., oligomycin, resveratrol) do so by inhibiting the mitochondrial F1 ATP synthase.

**ROLES OF AMPK IN CANCER AND IN VIRAL INFECTION**

The finding that LKB1, a known tumor suppressor, acted upstream of AMPK (Hawley et al. 2003; Woods et al. 2003) provided the first link between AMPK and cancer. AMPK activation causes a p53-dependent cell cycle arrest (Imamura et al. 2001) and inhibits essentially all biosynthetic pathways required for cell growth, including synthesis of fatty acids, phospholipids, proteins, and ribosomal RNA (Hardie 2007; Hoppe et al. 2009). Thus, AMPK activation would be expected to suppress cell growth and proliferation. Consistent with this, it was found that diabetics treated with metformin had a lower incidence of cancer than those on other medications (Evans et al. 2005). This association has been confirmed in several other retrospective studies, including one in which breast cancer patients already taking metformin for diabetes had a significantly better response to chemotherapy than diabetics not on metformin, as well as nondiabetics (Jiralerspong et al. 2009). Metformin, its more potent sister drug phenformin, and A-769662 (a direct AMPK activator developed by Abbott) also significantly delayed the onset of tumors in a tumor-prone mouse model (Huang et al. 2008). Since metformin/phenformin and A-769662 activate AMPK by distinct mechanisms, the possibility that this delay in tumorigenesis was due to “off-target” (i.e., AMPK-independent) effects seems unlikely. While the AMPK activators used in this latter study did delay tumorigenesis, all of the mice eventually developed tumors. How then do tumor cells eventually escape from the cytostatic effects of AMPK-activating drugs? One explanation may be that they acquire additional mutations that reduce or prevent continued AMPK activation. One such mutation would be loss of LKB1, which has been estimated to occur in up to 30% of non-small-cell lung cancers (Sanchez-Cespedes et al. 2002; Ji et al. 2007) and 20% of cervical cancers (Wingo et al. 2009). However, there may be other mechanisms. In one recent study, AMPK activation was found to be down-regulated compared with normal epithelium (based on immunohistochemistry using anti-pT172 antibody) in 318 out of 349 breast cancer biopsies (Hadad et al. 2009). The mechanisms responsible for down-regulation in these cases were not clear, although loss-of-function mutations in LKB1 appear to be rare in breast cancer, suggesting that other mechanisms may operate.

In some respects, viral infection of cells demonstrates analogies to tumorigenesis. In both cases, the biosynthetic machinery of the cell has been usurped by abnormal genes, by viral genes in the former case, and by oncogenic mutations or loss of tumor suppressors in the latter. The effects of viral infection on AMPK were recently studied using an in vitro model system in which a human hepatoma cell line was infected using hepatitis C
ROLE OF AMPK IN DIABETES, CANCER, AND VIRAL INFECTION

AMPK is a cellular energy sensor that, once activated by metabolic stresses, maintains energy homeostasis by switching on alternate catabolic pathways while inhibiting energy-consuming anabolic pathways, including cell growth and proliferation. AMPK occurs invariably under metabolic stresses, maintains energy homeostasis by binding of AMP at a carboxy-terminal site, Ser485 (Mankouri et al. 2010), which has been previously reported to inhibit phosphorylation at Thr172, and consequent activation by LKB1 (Homan et al. 2006). By transfecting DNA encoding a nonphosphorylatable S485A mutant of α1, it was shown that phosphorylation of Ser485 is required for viral replication (Mankouri et al. 2010). Since PKB/Akt is activated in many tumor cells (e.g., owing to mutation in PI 3-kinase or loss of the PI3-kinase phosphatase, PTEN), this may also be a mechanism by which AMPK is down-regulated in tumor cells, allowing unrestricted bio- synthisis without the restraining influence of AMPK. Interestingly, the long-term complications of chronic HCV infection include increased risk of hepatocellular carcinoma. Since AMPK is cytosstatic, the fact that the virus has already down-regulated AMPK may explain this deleterious consequence of chronic infection. It is tempting to speculate that other viruses associated with specific cancers, for example, human papillomavirus in cervical cancer, may also down-regulate AMPK.

CONCLUDING REMARKS

AMPK is a cellular energy sensor that, once activated by metabolic stresses, maintains energy homeostasis by switching on alternate catabolic pathways while inhibiting energy-consuming anabolic pathways, including cell growth and proliferation. AMPK occurs invariably as heterotrimeric complexes comprising a catalytic α subunit and regulatory β and γ subunits. AMPK is activated by phosphorylation of Thr172 by LKB1, which is promoted by binding of AMP or ADP to the AMPK-γ subunit, and by a further allosteric activation caused by binding of AMP at a different site on the γ subunit. Many drugs and xenobiotics activate AMPK, and in most cases these act as metabolic poisons that inhibit mitochondrial ATP synthesis and thus increase cellular ADP:ATP and AMP:ATP ratios. AMPK is likely to mediate most, if not all, of the tumor suppressor effects of LKB1, and the cytostatic effects of AMPK may explain findings that the antidiabetic drug metformin provides protection against the development of cancer. However, whether AMPK activators can be used to treat cancer once it has been diagnosed remains less certain, because many tumor cells appear to have acquired mechanisms to down-regulate AMPK. Viral infection of mammalian cells bears some analogies with tumorigenesis, and down-regulation of AMPK may both be necessary for viral infection and help to explain the promotion of tumors caused by chronic infection with some viruses.

REFERENCES


ROLE OF AMPK IN DIABETES, CANCER, AND VIRAL INFECTION


Adenosine Monophosphate–Activated Protein Kinase: A Central Regulator of Metabolism with Roles in Diabetes, Cancer, and Viral Infection

D.G. Hardie

*Cold Spring Harb Symp Quant Biol* 2011 76: 155-164 originally published online November 9, 2011

Access the most recent version at doi:10.1101/sqb.2011.76.010819

**References**

This article cites 106 articles, 46 of which can be accessed free at: [http://symposium.cshlp.org/content/76/155.full.html#ref-list-1](http://symposium.cshlp.org/content/76/155.full.html#ref-list-1)

**License**

**Email Alerting Service**

Receive free email alerts when new articles cite this article - sign up in the box at the top right corner of the article or [click here](http://symposium.cshlp.org/subscriptions).

To subscribe to *Cold Spring Harbor Symposia on Quantitative Biology* go to: [http://symposium.cshlp.org/subscriptions](http://symposium.cshlp.org/subscriptions)

© 2011 Cold Spring Harbor Laboratory Press; all rights reserved